Octagam Immune Globulin (Human)
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Octagam Immune Globulin (Human)
- Generic name
- IMMUNE GLOBULIN
- Manufacturer
- Octapharma USA Inc
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- de00abeb-d635-eddc-b603-10708ecef5aa
- SPL ID
- 1ceaed06-d43c-a23d-a4e0-dce0de4ad7f0
- Version
- 11
- Effective date
- 2022-04-19
- Source export date
- 2026-11-13
- Source partition
- 10
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:15:33
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125062 | derived:openfda.application_number |
| application number | BLA125062 | openfda.application_number | |
| brand name | Octagam Immune Globulin (Human) | openfda.brand_name | |
| generic name | IMMUNE GLOBULIN | openfda.generic_name | |
| manufacturer name | Octapharma USA Inc | openfda.manufacturer_name | |
| ndc | package | 68982-840-03 | openfda.package_ndc |
| ndc | package | 68982-840-02 | openfda.package_ndc |
| ndc | package | 68982-840-01 | openfda.package_ndc |
| ndc | package | 68982-840-05 | openfda.package_ndc |
| ndc | package | 68982-840-04 | openfda.package_ndc |
| ndc | product | 68982-840 | openfda.product_ndc |
| ndc11 | package | 68982084001 | derived:openfda.package_ndc |
| ndc11 | package | 68982084002 | derived:openfda.package_ndc |
| ndc11 | package | 68982084003 | derived:openfda.package_ndc |
| ndc11 | package | 68982084005 | derived:openfda.package_ndc |
| ndc11 | package | 68982084004 | derived:openfda.package_ndc |
| rxcui | 1809643 | openfda.rxcui | |
| rxcui | 1809648 | openfda.rxcui | |
| rxcui | 1809652 | openfda.rxcui | |
| rxcui | 1809447 | openfda.rxcui | |
| rxcui | 1809651 | openfda.rxcui | |
| rxcui | 1809642 | openfda.rxcui | |
| rxcui | 1809647 | openfda.rxcui | |
| rxcui | 1809463 | openfda.rxcui | |
| rxcui | 1809649 | openfda.rxcui | |
| rxcui | 1809456 | openfda.rxcui | |
| spl id | 1ceaed06-d43c-a23d-a4e0-dce0de4ad7f0 | id | |
| spl set id | de00abeb-d635-eddc-b603-10708ecef5aa | set_id | |
| unii | 66Y330CJHS | openfda.unii |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE Thrombosis may occur with immune globulin intravenous (IGIV) products, including Octagam 5% liquid. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. (See WARNING and PRECAUTIONS [ 5.5 ], PATIENT COUNSELING INFORMATION [ 17 ]) Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IGIV products, including Octagam 5% liquid. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV product containing sucrose. Octagam 5% liquid does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or acute renal failure, administer Octagam 5% liquid at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. (See DOSAGE and ADMINISTRATION [ 2 ], WARNINGS and PRECAUTIONS [ 5.5 ]) WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE See full prescribing information for complete boxed warning. Thrombosis may occur with immune globulin intravenous (IGIV) products, including Octagam 5% liquid. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with IGIV products, including Octagam 5% liquid. Renal dysfunction and acute renal failure occur more commonly with IGIV products containing sucrose. Octagam 5% liquid does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or acute renal failure administer Octagam 5% liquid at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS IgA deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions. Epinephrine should be available immediately to treat any acute severe hypersensitivity reactions. ( 5.1 ) Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure. ( 5.2 ) Falsely elevated blood glucose readings may occur during and after the infusion of Octagam 5% liquid with some glucometer and test strip systems. ( 5.3 ) Hyperproteinemia, increased serum viscosity and hyponatremia occur in patients receiving IGIV therapy. ( 5.4 ) Thrombosis may occur following treatment with immune globulin products, including Octagam 5% liquid. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. ( 5.5 ) Aseptic Meningitis Syndrome has been reported with Octagam 5% liquid and other IGIV treatments, especially with high doses or rapid infusion. ( 5.6 ) Hemolytic anemia can develop subsequent to IGIV therapy due to enhanced RBC sequestration. ( 5.7 ) IGIV recipients should be monitored for pulmonary adverse reactions (TRALI). ( 5.8 ) The product is made from human plasma and may contain infectious agents, e.g. viruses and, theoretically, the Creutzfeldt-Jakob disease agent. ( 5.9 ) The passive transfer of antibodies may confound the results of serological testing ( 5.11 ). 5.1 Hypersensitivity Reactions Severe hypersensitivity reactions may occur [ 1 ] (See Contraindications [ 4 ] ) . In case of hypersensitivity, discontinue Octagam 5% liquid infusion immediately and institute appropriate treatment. Always have medications such as epinephrine available for immediate treatment of acute severe hypersensitivity reactions. IgA deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactoid reactions when administered Octagam 5% liquid (See Contraindications [ 4 ]) . Patients known to have corn allergies should avoid using Octagam 5% liquid (See Contraindications [ 4 ]). 5.2 Renal Failure Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur upon use of IGIV products in predisposed patients. Assure that patients are not volume depleted prior to the initiation of the infusion of Octagam 5% liquid. Assess renal function, including a measurement of blood urea nitrogen (BUN)/serum creatinine, prior to the initial infusion of Octagam 5% liquid and again at appropriate intervals thereafter. It is particularly important to do periodic monitoring of renal function tests and urine output in patients judged to have a potential increased risk of developing acute renal failure. Consider discontinuation of the infusion if renal function deteriorates. (See Patient Counseling Information [ 17 ].) For patients judged to be at risk for developing renal dysfunction and/or at risk of developing thrombotic events (such as those with diabetes mellitus or hypovolemia, those who are obese, those who use concomitant nephrotoxic medicinal products, or those who are over 65 years of age), administer Octagam 5% liquid at the minimum rate of infusion practicable (less than 0.07 mL/kg/min (3.3 mg/kg/min) (See Boxed Warning, and Dosage and Administration [ 2.3 ]). 5.3 Blood Glucose Monitoring Some types of blood glucose testing systems (for example, those based on the glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase methods) falsely interpret the maltose contained in Octagam 5% liquid as glucose. This has resulted in falsely elevated glucose readings and, consequently, in the inappropriate administration of insulin, resulting in life-threatening hypoglycemia. Further, cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings. Therefore, always use a glucose-specific method for the measurement of blood glucose, when administering Octagam 5% liquid. Carefully review the product information of the blood glucose testing system, including that of the test strips, to determine if the system is appropriate for use with maltose-containing parenteral products. If any uncertainty exists, contact the manufacturer of the testing system to determine if the system is appropriate for use with maltose-containing parenteral products. [ 2 ] 5.4 Hyperproteinemia Hyperproteinemia, increased serum viscosity and hyponatremia may occur in patients receiving IGIV therapy, including Octagam 5% liquid. The hyponatremia is likely to be a pseudohyponatremia as demonstrated by a decreased calculated serum osmolality or elevated osmolar gap. Distinguishing true hyponatremia from pseudohyponatremia is clinically critical, as treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity and a disposition to thromboembolic events [ 3 ]. 5.5 Thrombotic events Thrombosis may occur following treatment with immune globulin products, including Octagam 5% liquid. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, administer Octagam 5% liquid at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [ 4 ], [ 5 ], [ 6 ]. (See Boxed Warning, Dosage and Administration [ 2 ], Patient Counseling Information [ 17 ]) 5.6 Aseptic meningitis syndrome Aseptic meningitis syndrome (AMS) has been reported to occur infrequently in association with IGIV treatment, including Octagam 5% liquid. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae. The syndrome usually begins within several hours to two days following IGIV treatment and rapid infusion. It is characterized by symptoms and signs including severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea and vomiting. Cerebrospinal fluid (CSF) studies are frequently positive with pleocytosis up to several thousand cells per cu mm, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dl. Conduct a thorough neurological examination on patients exhibiting such signs and symptoms, including CSF studies, to rule out other causes of meningitis. AMS may occur more frequently in association with high doses (2 g/kg) and/or rapid infusion of IGIV. It appears that patients with a history of migraine may be more susceptible. [ 7 ] (See Patient Counseling Information [ 17 ]). 5.7 Hemolysis Octagam 5% liquid may contain blood group antibodies, which may act as hemolysins and induce in vivo coating of red blood cells with immunoglobulin, causing a positive direct antiglobulin reaction and, rarely, hemolysis [ 8 ]. Delayed hemolytic anemia can develop subsequent to IGIV therapy due to enhanced RBC sequestration and acute hemolysis, consistent with intravascular hemolysis, has been reported. Cases of severe hemolysis-related renal dysfunction/failure or disseminated intravascular coagulation have occurred following infusion of IGIV (See Adverse Reactions [ 6 ]) [ 9 ]. The following risk factors may be associated with the development of hemolysis following IGIV administration: high doses (e.g. ≥ 2 g/kg), given either as a single administration or divided over several days, and non-O blood group. Other individual patient factors, such as an underlying inflammatory state (as may be reflected by, for example, elevated C-reactive protein or erythrocyte sedimentation rate), have been hypothesized to increase the risk of hemolysis following administration of IGIV but their role is uncertain. Hemolysis has been reported following administration of IGIV for a variety of indications. Closely monitor patients for clinical signs and symptoms of hemolysis, particularly patients with risk factors noted above. Consider appropriate laboratory testing in higher risk patients, including measurement of hemoglobin or hematocrit prior to infusion and within approximately 36 to 96 hours post infusion. If clinical signs and symptoms of hemolysis or a significant drop in hemoglobin or hematocrit have been observed, perform confirmatory laboratory testing. If transfusion is indicated for patients who develop hemolysis with clinically compromising anemia after receiving IGIV, perform adequate cross-matching to avoid exacerbating on-going hemolysis. (See Patient Counseling Information [ 17 ]) . 5.8 Transfusion-Related Acute Lung Injury (TRALI) Noncardiogenic pulmonary edema [Transfusion-Related Acute Lung Injury (TRALI)] may occur in patients treated with IGIV products, including Octagam 5% liquid [ 10 ]. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever and typically occurs within 1-6 hours after transfusion. Monitor patients for pulmonary adverse reactions (See Patient Counseling Information [ 17 ]) . If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient serum. Patients with TRALI may be managed using oxygen therapy with adequate ventilatory support. 5.9 Transmissible Infectious Agents Because Octagam 5% liquid is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk of infectious agent transmission has been reduced by screening plasma donors for prior exposure to certain viruses, testing for the presence of certain current virus infections, and including virus inactivation/removal steps in the manufacturing process for Octagam 5% liquid. Report all infections thought to possibly be transmitted by Octagam 5% liquid to Octapharma USA Inc. at 1-866-766-4860 . Always discuss the risks and benefits of this product with the patient, before prescribing or administering it to the patient (See Patient Counseling Information [ 17 ]). 5.10 Laboratory Tests Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of BUN and serum creatinine, before the initial infusion of Octagam 5% liquid and at appropriate intervals thereafter. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies, because of the potentially increased risk of thrombosis. If signs and/or symptoms of hemolysis are present after an infusion of Octagam 5% liquid, perform appropriate laboratory testing for confirmation. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies and anti-HLA antibodies in both the product and patient’s serum. 5.11 Interference with Laboratory Tests After infusion of IgG, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs) test.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions observed with Octagam 5% liquid treatment during clinical trial (> 5%) were headache and nausea. The most serious adverse reactions observed with Octagam 5% liquid treatment have been immediate anaphylactic reactions (see Warning and Precautions [ 5.1 ]), thromboembolic events ( Warning and Precautions [ 5.5 ]), aseptic meningitis ( Warnings and Precautions [ 5.6 ]), and hemolytic anemia ( Warnings and Precautions [ 5.7 ]). Most common adverse reactions with an incidence of > 5% during a clinical trial were headache and nausea. ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Octapharma USA Inc. at 1-866-766-4860 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a product cannot be directly compared to rates in the clinical trials of another product and may not reflect the rates observed in clinical practice. The clinical trial database includes a multi-center, study in 46 children and adults with PI. Subjects participated in the study for a mean of 346 days and received 300 to 450 mg/kg every 21 days or 400 to 600 mg/kg every 28 days. Infusions were initiated at a rate of 30 mg/kg/hr for the first 30 minutes, and, if tolerated, could be advanced to a maximum tolerated rate not exceeding 200 mg/kg/hr. Over half of the subjects were male (n=28; 61%), and more than half were on the 28-day infusion schedule (n=27; 59%). The mean age of subjects was 31.5 years. Pre-medications were used in 165 (25.2%) out of 654 infusions and in 14 (30.4%) out of 46 patients. Infusions were slowed or interrupted in 9 out of 489 infusions (1.84%) without pre-medication and in 10 out of 165 infusions (6.06%) with pre-medication. Five out of 32 (15.63%) patients who never received any pre-medication had at least one slowed or interrupted infusion, whereas 9 out of 14 (64.29%) patients who received pre-medication at least once also had a slowed or interrupted infusion. During the described trial 12 serious adverse events were reported in 6 patients. Eleven SAEs were assessed as being not related. One serious adverse event (Calculus renal NOS) war reported just before the next infusion, and was not temporarily related to the previous infusion. No subject withdrew from the study due to an adverse event or adverse reaction. The adverse reactions (= adverse events that were assessed as treatment related) reported by at least 5% of subjects during the 12-month treatment are given in Table 2 below. Table 2: Adverse Reactions Occurring in ≥ 5% of Subjects Receiving Octagam 5% No. of subjects (%) No. of events (%) Total 46 (100%) 71 (100%) Headache NOS 7 (15%) 18 (25%) Nausea 3 (7%) 4 (6%) Laboratory Abnormalities Standard clinical laboratory evaluations were performed in the study. Three subjects (7%) had incidences of AST (>2.5 x ULN) which were all assessed as clinically non-significant. No subject had a positive Coombs test or other signs of hemolysis (such as drop of hemoglobin of ≥ 2 g/dL) during the study. 6.2 Postmarketing Experience Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. The following adverse reactions have been identified during post-approval use of Octagam 5% liquid. Blood and lymphatic system disorders Leukopenia, hemolytic anemia Immune system disorders Hypersensitivity, anaphylactic shock, anaphylactic reaction, anaphylactoid reaction, angioedema, face oedema Metabolic and nutritional disorders Fluid overload, (pseudo)hyponatremia Psychiatric disorders Agitation, confusional state, anxiety, nervousness Nervous system disorders Cerebrovascular accident, loss of consciousness, speech disorder, meningitis aseptic, migraine, dizziness, paresthesia, hypoesthesia, tremor, photophobia Eye disorders Visual impairment Cardiac disorders Myocardial infarction, angina pectoris, bradycardia, tachycardia, palpitations, cyanosis Vascular disorders Hypotension, thrombosis, circulatory collapse, peripheral circulatory failure, hypertension, phlebitis, pallor Respiratory, thoracic and mediastinal disorders Respiratory failure, pulmonary embolism, pulmonary oedema, bronchospasm, dyspnea, cough, hypoxia Gastrointestinal disorders Vomiting, diarrhea, abdominal pain Skin and subcutaneous tissue disorders Eczema, skin exfoliation, urticaria, rash, rash erythematous, dermatitis, erythema, pruritus, alopecia Musculoskeletal and connective tissue disorders Back pain, arthralgia, myalgia, pain in extremity, neck pain, muscle spasm, muscular weakness, musculoskeletal stiffness Renal and urinary disorders Renal failure acute, renal pain General disorders and administration site conditions Fatigue, oedema, injection site reaction, pyrexia, influenza-like illness, chills, chest pain, chest discomfort, hot flush, flushing, feeling hot, feeling cold, hyperhidrosis, malaise, lethargy, asthenia, burning sensation Investigations Hepatic enzymes increased, blood glucose false positive Injury, poisoning and procedural complications Transfusion-related acute lung injury
adverse reactions table
<table><thead><tr><td align="left" valign="bottom" styleCode="Toprule Botrule Lrule Rrule"/><td align="center" valign="bottom" styleCode="Toprule Botrule Lrule Rrule"> No. of subjects (%)</td><td align="center" valign="bottom" styleCode="Toprule Botrule Lrule Rrule"> No. of events (%)</td></tr></thead><tbody><tr><td align="left" valign="bottom" styleCode="Toprule Botrule Lrule Rrule"> Total</td><td align="center" valign="bottom" styleCode="Toprule Botrule Lrule Rrule"> 46 (100%)</td><td align="center" valign="bottom" styleCode="Toprule Botrule Lrule Rrule"> 71 (100%)</td></tr><tr><td align="left" valign="bottom" styleCode="Toprule Botrule Lrule Rrule"> Headache NOS</td><td align="center" valign="bottom" styleCode="Toprule Botrule Lrule Rrule"> 7 (15%)</td><td align="center" valign="bottom" styleCode="Toprule Botrule Lrule Rrule"> 18 (25%)</td></tr><tr><td align="left" valign="bottom" styleCode="Toprule Botrule Lrule Rrule"> Nausea</td><td align="center" valign="bottom" styleCode="Toprule Botrule Lrule Rrule"> 3 (7%)</td><td align="center" valign="bottom" styleCode="Toprule Botrule Lrule Rrule"> 4 (6%)</td></tr></tbody></table>
adverse reactions table
<table><thead><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Blood and lymphatic system disorders</content></content> Leukopenia, hemolytic anemia</td></tr></thead><tbody><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Immune system disorders </content></content> Hypersensitivity, anaphylactic shock, anaphylactic reaction, anaphylactoid reaction, angioedema, face oedema</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Metabolic and nutritional disorders</content></content> Fluid overload, (pseudo)hyponatremia</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Psychiatric disorders</content></content> Agitation, confusional state, anxiety, nervousness</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Nervous system disorders</content></content> Cerebrovascular accident, loss of consciousness, speech disorder, meningitis aseptic, migraine, dizziness, paresthesia, hypoesthesia, tremor, photophobia</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Eye disorders</content></content> Visual impairment</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Cardiac disorders</content></content> Myocardial infarction, angina pectoris, bradycardia, tachycardia, palpitations, cyanosis</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Vascular disorders</content></content> Hypotension, thrombosis, circulatory collapse, peripheral circulatory failure, hypertension, phlebitis, pallor</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Respiratory, thoracic and mediastinal disorders</content></content> Respiratory failure, pulmonary embolism, pulmonary oedema, bronchospasm, dyspnea, cough, hypoxia</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Gastrointestinal disorders</content></content> Vomiting, diarrhea, abdominal pain</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Skin and subcutaneous tissue disorders</content></content> Eczema, skin exfoliation, urticaria, rash, rash erythematous, dermatitis, erythema, pruritus, alopecia</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Musculoskeletal and connective tissue disorders</content></content> Back pain, arthralgia, myalgia, pain in extremity, neck pain, muscle spasm, muscular weakness, musculoskeletal stiffness</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Renal and urinary disorders</content></content> Renal failure acute, renal pain</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> General disorders and administration site conditions</content></content> Fatigue, oedema, injection site reaction, pyrexia, influenza-like illness, chills, chest pain, chest discomfort, hot flush, flushing, feeling hot, feeling cold, hyperhidrosis, malaise, lethargy, asthenia, burning sensation</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Investigations</content></content> Hepatic enzymes increased, blood glucose false positive</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Injury, poisoning and procedural complications </content></content> Transfusion-related acute lung injury</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.